NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
J Clin Oncol. 2024 Apr 24:JCO2301983. doi: 10.1200/JCO.23.01983. Online ahead of print. ABSTRACT PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients …